Results and perinatal outcomes from 189 ICSI cycles of couples with asthenozoospermic men and flagellar defects assessed by transmission electron microscopy.


Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
11 2023
Historique:
received: 13 04 2023
revised: 09 06 2023
accepted: 01 08 2023
medline: 13 11 2023
pubmed: 25 9 2023
entrez: 24 9 2023
Statut: ppublish

Résumé

Do patients presenting with flagella ultrastructural defects as assessed by electron microscopy, and defined within three phenotypes (dysplasia of the fibrous sheath [DFS], primary flagellar dyskinesia [PFD] and non-specific flagellar abnormalities [NSFA]), have decreased chances of success in intracytoplasmic sperm injection (ICSI) or adverse obstetric and neonatal outcomes? Retrospective analysis of 189 ICSI cycles from 80 men with spermatozoa flagellum ultrastructural defects (DFS [n = 16]; PFD [n = 14]; NSFA [n = 50] compared with a control group (n = 97). Cycles were cumulatively analysed. All fresh and frozen embryo transfers resulting from each ICSI attempt were included. The effect of transmission electron microscopy (TEM) phenotype on the main ICSI outcomes was assessed by a multivariate logistic regression combined with a generalized linear mixed model to account for the non-independence of the observations. No predictive value of TEM phenotype was found on the main outcomes of ICSI, namely fertilization rates, pregnancy and delivery rates, and cumulative pregnancy and delivery rates. Cumulative pregnancy rates ranged from 29.0-43.3% in the different TEM phenotype subgroups compared with 36.8% in the control group. Cumulative live birth rates ranged from 24.6-36.7% compared with 31.4% in the control group. No increase was found in miscarriages, preterm births, low birth weights or birth abnormalities. Data on the cumulative chances of success in ICSI of patients with ultrastructural flagellar defects, a rare cause of male infertility often associated with an underlying genetic cause, are reassuring, as are obstetrical and neonatal outcomes in this population.

Identifiants

pubmed: 37742467
pii: S1472-6483(23)00428-5
doi: 10.1016/j.rbmo.2023.103328
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103328

Informations de copyright

Copyright © 2023 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Auteurs

Angèle Boursier (A)

CHU Lille, Institut de Biologie de la Reproduction-Spermiologie-CECOS, F-59000, Lille, France; Inserm UMR-S 1172, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille, France.

Augustin Boudry (A)

CHU Lille, Centre de Biologie-Pathologie, Laboratoire d'hématologie, F-59000, Lille, France; Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, France.

Valérie Mitchell (V)

CHU Lille, Institut de Biologie de la Reproduction-Spermiologie-CECOS, F-59000, Lille, France.

Anne Loyens (A)

Inserm UMR-S 1172, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille, France.

Nathalie Rives (N)

Normandie Univ, UNIROUEN, Inserm U1239 Team "Adrenal and Gonadal Physiopathology".

Alexandre Moerman (A)

CHU Lille, Service de Génétique Clinique, Institut de Génétique Médicale, Hôpital Jeanne de Flandre, Lille, France.

Lucie Thomas (L)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Childhood Genetic Disorders, Département de Génétique Médicale, Assistance Publique - Hôpitaux de Paris, Hôpital Trousseau, Paris 75012, France.

Estelle Escudier (E)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Childhood Genetic Disorders, Département de Génétique Médicale, Assistance Publique - Hôpitaux de Paris, Hôpital Trousseau, Paris 75012, France.

Aminata Toure (A)

Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France.

Marjorie Whitfield (M)

Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France.

Charles Coutton (C)

Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France; UM de Génétique Chromosomique, Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France.

Guillaume Martinez (G)

Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France; UM de Génétique Chromosomique, Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France.

Pierre F Ray (PF)

Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France; UM GI-DPI, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France.

Zine-Eddine Kherraf (ZE)

Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38000 Grenoble, France; UM GI-DPI, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France.

Stéphane Viville (S)

Laboratoire de Génétique Médicale LGM, Institut de Génétique Médicale d'Alsace IGMA, INSERM UMR 1112, Université de Strasbourg, Strasbourg, France; Laboratoire de Diagnostic Génétique, Unité de Génétique de l'Infertilité (UF3472), Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Marie Legendre (M)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Childhood Genetic Disorders, Département de Génétique Médicale, Assistance Publique - Hôpitaux de Paris, Hôpital Trousseau, Paris 75012, France.

Thomas Smol (T)

CHU Lille, Service de Génétique Clinique, Institut de Génétique Médicale, Hôpital Jeanne de Flandre, Lille, France; Université de Lille, EA 7364-RADEME, Lille, France.

Geoffroy Robin (G)

Université de Lille, CHU Lille, Service de Gynécologie Médicale Orthogénie et Sexologie, F-59000, Lille, France.

Anne-Laure Barbotin (AL)

CHU Lille, Institut de Biologie de la Reproduction-Spermiologie-CECOS, F-59000, Lille, France; Inserm UMR-S 1172, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille, France. Electronic address: annelaure.barbotin@chru-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH